Feed HLNCF
HL

Haleon plc

HLNCF · OTC

$4.46 +1.36% (+$0.06)
1M -10.75%
Market Cap £29.4B
P/E Ratio 19.29x
Div. Yield 3.00%
ROE 9.40%

Bulios Fair Price

$2.43

45.5% downside

Current Price

$4.46

Undervalued Fair Value Overvalued

According to Bulios Fair Price, HLNCF is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Strong
7/9
Valuation
73 /100
Cheap
EV/EBITDA 14.12x
P/S 2.66x
P/B 1.79x
Growth
50 /100
Stable
Rev. growth 0.52%
FCF growth 5.11%
Book val. growth 0.19%
Profitability
92 /100
Strong
Net margin 13.81%
Op. margin 20.49%
FCF margin 20.98%
Quality
37 /100
Average
ROE 9.40%
ROA 4.66%
Asset turnover 0.34x
Debt
59 /100
Moderate
Current ratio 0.92x
Int. coverage 7.07x
Net debt/EBITDA 2.80x
Stability
72 /100
Stable
Rev. volatility 3.12%
EPS volatility 22.84%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about HLNCF
Online

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Brian James McNamara

Employees

24,561

Headquarters

Weybridge

Upcoming events

04 MAR

Earnings

Upcoming earnings report

153d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.